. Unresolved toxicities from prior anticancer therapy defined as having not resolved to baseline or to Grade  or , or to levels dictated in the inclusion/exclusion criteria with the exception of alopecia;
Unresolved toxicities from prior antitumor therapy, defined as not having resolved to CTCAE, version . grade  (with the exception of myelosuppression, eg, neutropenia, anemia, thrombocytopenia), or to levels dictated in the eligibility criteria with the exception of alopecia or toxicities from prior antitumor therapy that are considered irreversible (defined as having been present and stable for >  months) which may be allowed if they are not otherwise described in the exclusion criteria AND there is agreement to allow by both the investigator and sponsor.
Unresolved toxicities from prior anti-cancer therapy, defined as having not resolved to Common Terminology Criteria for Adverse Event (CTCAE, version .), grade =< , or to the levels dictated in the inclusion/exclusion criteria with the exception of alopecia
Unresolved toxicities from prior anti-cancer therapy, defined as having not resolved to Common Terminology Criteria for Adverse Event (CTCAE, version ), grade =< , or to the levels dictated in the inclusion/exclusion criteria with the exception of alopecia
Unresolved toxicities from prior antitumor therapy, defined as not having resolved to CTCAE, version . grade 
Unresolved toxicities from prior anti-tumor therapy (defined as not having resolved to Common Terminology Criteria for Adverse Events (CTCAE) version . grade , or to levels dictated in the eligibility criteria) with the exception of alopecia or toxicities from prior anti-tumor therapy that are considered irreversible [defined as having been present and stable for >  days] which may be allowed if they are not otherwise described in the exclusion criteria AND there is agreement to allow by both the investigator and Amgen
Unresolved toxicities from prior antitumor therapy, defined as not having resolved to CTCAE, version . grade  (with the exception of myelosuppression, e.g., neutropenia, anemia, thrombocytopenia), or to levels dictated in the eligibility criteria with the exception of alopecia or toxicities from prior antitumor therapy that are considered irreversible (defined as having been present and stable for >  months) which may be allowed if they are not otherwise described in the exclusion criteria AND there is agreement to allow by both the investigator and sponsor
Unresolved toxicities from prior anti-cancer therapy, defined as having not resolved to Common Terminology Criteria for Adverse Event (CTCAE, version [v]), grade =< , or to the levels dictated in the inclusion/exclusion criteria with the exception of alopecia
Unresolved toxicities from prior anti-cancer therapy, defined as having not resolved to Common Terminology Criteria for Adverse Event (CTCAE, version [v].), grade =< , or to the levels dictated in the inclusion/exclusion criteria with the exception of alopecia
Unresolved toxicities from prior anti-cancer therapy, defined as having not resolved to Common Terminology Criteria for Adverse Event (CTCAE, version ), grade =< , or to the levels dictated in the inclusion/exclusion criteria with the exception of alopecia
Unresolved toxicities from prior anticancer therapy, defined as having not resolved to Common Terminology Criteria for Adverse Event (CTCAE, version .), grade  or , or to the levels dictated in the inclusion/exclusion criteria, with the exception of alopecia
 Unresolved toxicity from prior anti-tumor therapy, defined as not having resolved to CTCAE version . grade , or to levels dictated in the eligibility criteria with the exception of alopecia or toxicities from prior anti-tumor therapy that are considered irreversible (defined as having been present and stable for >  days) which may be allowed if they are not otherwise described in the exclusion criteria AND there is agreement to allow by both the investigator and the Amgen Medical Monitor.
Unresolved toxicities from prior anti-cancer therapy, defined as having not resolved to Common Terminology Criteria for Adverse Event (CTCAE, version .), grade  or less, or to the levels dictated in the inclusion/exclusion criteria with the exception of alopecia
Subjects who have not recovered from toxicities from prior anti-tumor therapy, defined as not having resolved to Common Terminology Criteria for Adverse Events (CTCAE) version . grade  or , or to levels dictated in the eligibility criteria with the exception of alopecia (grade  or  toxicities from prior antitumor therapy that are considered irreversible [defined as having been present and stable for >  months], such as grade  chemotherapy-induced peripheral neuropathy, may be allowed if they are not otherwise described in the exclusion criteria AND there is agreement to allow by both the investigator and sponsor)
Unresolved toxicities from prior anti-cancer therapy, defined as having not resolved to Common Terminology Criteria for Adverse Event (CTCAE, version ), grade =< , or to the levels dictated in the inclusion/exclusion criteria with the exception of alopecia
Unresolved toxicities from prior anti-cancer therapy, defined as having not resolved to Common Terminology Criteria for Adverse Event (CTCAE, version ), grade =< , or to the levels dictated in the inclusion/exclusion criteria with the exception of alopecia
Unresolved toxicities from prior anticancer therapy, defined as having not resolved to NCI CTCAE v . < Grade  or normalized to baseline, or to levels dictated in the inclusion/exclusion criteria, with the exception of alopecia.
Unresolved toxicities from prior anti-cancer therapy, defined as having not resolved to Common Terminology Criteria for Adverse Event (CTCAE, version ), grade  or , or to the levels dictated in the inclusion/exclusion criteria with the exception of alopecia
Unresolved toxicities from prior anti-tumor therapy, defined as not having resolved to Common Terminology Criteria for Adverse Events (CTCAE) version . grade  or , or to levels dictated in the eligibility criteria with the exception of alopecia (grade  or  toxicities from prior antitumor therapy that are considered irreversible [defined as having been present and stable for >  months], such as ifosfamide-related proteinuria, may be allowed if they are not otherwise described in the exclusion criteria AND there is agreement to allow by both the investigator and sponsor)
Unresolved toxicities from prior anti-cancer therapy, defined as having not resolved to Common Terminology Criteria for Adverse Event (CTCAE, version ), grade =< , or to the levels dictated in the inclusion/exclusion criteria with the exception of alopecia
Unresolved toxicities from prior anti-cancer therapy, defined as having not resolved to Common Terminology Criteria for Adverse Event (CTCAE, version ), grade =< , or to the levels dictated in the inclusion/exclusion criteria with the exception of alopecia
Prior systemic chemotherapy for the study cancer (sarcoma); note that prior chemotherapy for a different cancer is allowable; however, unresolved toxicities from prior anti-tumor therapy, defined as not having resolved to Common Terminology Criteria for Adverse Events (CTCAE) version . grade  or , or to levels dictated in the eligibility criteria with the exception of alopecia (grade  or  toxicities from prior anti-tumor therapy that are considered irreversible [defined as having been present and stable for >  months], such as ifosfamide-related proteinuria, may be allowed if they are not otherwise described in the exclusion criteria AND there is agreement to allow by both the investigator and sponsor)
Unresolved toxicities from prior anti-cancer therapy, defined as having not resolved to Common Terminology Criteria for Adverse Event (CTCAE, version .), grade  or , or to the levels dictated in the inclusion/exclusion criteria with the exception of alopecia
Known unresolved toxicities due to prior anticancer therapy, defined as not having resolved to grade  or  (by Common Terminology Criteria for Adverse Events [CTCAE] version  criteria), unless otherwise defined in the inclusion/exclusion criteria with the exception of alopecia
Unresolved toxicities from prior anticancer therapy, defined as having not resolved to Common Terminology Criteria for Adverse Event (CTCAE, version .), Grade  or , unless otherwise defined in the inclusion/exclusion criteria with the exception of alopecia.
Unresolved toxicities from prior anti-cancer therapy, defined as having not resolved to Common Terminology Criteria for Adverse Event (CTCAE, version ), grade =< , or to the levels dictated in the inclusion/exclusion criteria with the exception of alopecia
Unresolved toxicities from prior anti-cancer therapy, defined as having not resolved to CTCAE Grade  or , or to the levels dictated in the eligibility criteria with the exception of alopecia
Unresolved toxicities from prior anti-cancer therapy, defined as having not resolved to Common Terminology Criteria for Adverse Event (CTCAE, version .), grade =< , or to the levels dictated in the inclusion/exclusion criteria with the exception of alopecia
EXCLUSION CRITERIA (PRIOR TO IBRUTINIB ADMINISTRATION): Unresolved toxicities from prior anti cancer therapy, defined as having not resolved to Common Terminology Criteria for Adverse Event (CTCAE, version ), grade =< , or to the levels dictated in the inclusion/exclusion criteria with the exception of alopecia
